US 12,441,687 B2
Drp1-filamin complex formation inhibitors
Akio Ojida, Fukuoka (JP); Naoya Shindo, Fukuoka (JP); Akiyuki Nishimura, Fukuoka (JP); and Motohiro Nishida, Aichi (JP)
Assigned to RDISCOVERY, LLC, Seattle, WA (US)
Appl. No. 17/595,817
Filed by RDISCOVERY, LLC, Seattle, WA (US)
PCT Filed May 26, 2020, PCT No. PCT/JP2020/020744
§ 371(c)(1), (2) Date Nov. 24, 2021,
PCT Pub. No. WO2020/241638, PCT Pub. Date Dec. 3, 2020.
Claims priority of application No. 2019-103034 (JP), filed on May 31, 2019.
Prior Publication US 2022/0169613 A1, Jun. 2, 2022
Int. Cl. C07D 213/80 (2006.01); C07D 211/90 (2006.01); C07D 401/12 (2006.01)
CPC C07D 213/80 (2013.01) [C07D 211/90 (2013.01); C07D 401/12 (2013.01)] 93 Claims
 
1. A compound of Formula (I):

OG Complex Work Unit Chemistry
or a pharmacologically acceptable salt thereof or a solvate of them, wherein:
R1 is phenyl substituted with one to three substituents each of which is independently NO2, NH2, OH, C1-C6 alkyl, C1-C6 haloalkyl, or C1-C6 alkoxyalkyl, provided that at least one substituent is NO2 or NH2;
R2 is H, C1-C6 alkyl, C1-C6 haloalkyl, or C1-C6 alkoxyalkyl;
R3 is H, C1-C6 alkyl, C1-C6 haloalkyl, or C1-C6 alkoxyalkyl;
R4 is C1-C6 alkyl or C1-C6 haloalkyl;
R5 is phenyl or pyridinyl, wherein the phenyl or pyridinyl is unsubstituted or substituted with one to three substituents each of which is independently NO2, NH2, OH, C1-C6 alkyl, C1-C6 haloalkyl, or C1-C6 alkoxyalkyl;
either (i) bond a is present and bonds b and c are absent or (ii) bonds b and c are present and bond a is absent;
A is NH when bond a is present and N when bonds b and c are present;
m is an integer from 1 to 4; and
n is an integer from 1 to 3;
provided that the compound is other than

OG Complex Work Unit Chemistry
 
64. A pharmaceutical composition comprising the compound, pharmacologically acceptable salt or solvate of claim 1 and one or more pharmaceutically acceptable carriers.